RFWA
BMRN icon

RPg Family Wealth Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

RPg Family Wealth Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-121
Closed -$10.6K – 297
2017
Q1 		$10.6K Buy
+121
New +$10.8K 0.01% 258

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RPg Family Wealth Advisory's BMRN Position: Q2 2017 in Review

RPg Family Wealth Advisory sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2017, closing a stake of 121 shares — an estimated $10.6K sold.

RPg Family Wealth Advisory first reported a position in BMRN in Q1 2017 and held it in 1 quarter. The position peaked at $10.6K in Q1 2017. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

  • RPg Family Wealth Advisory reported no remaining BioMarin Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • RPg Family Wealth Advisory sold 121 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $10.6K.
  • RPg Family Wealth Advisory first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • RPg Family Wealth Advisory's BioMarin Pharmaceuticals position peaked at $10.6K in Q1 2017.
  • 426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on RPg Family Wealth Advisory's 13F filing for Q2 2017, filed 14 Aug 2017.